MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Berkeley Lights Cash Conversion Cycle 2011-2026 | BLI
Annual Cash Conversion Cycle Berkeley Lights
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 214 | 171 | 107 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 214 | 107 | 164 |
Quarterly Cash Conversion Cycle Berkeley Lights
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 420 | 442 | - | 180 | 184 | 199 | - | 105 | 141 | 157 | 54.3 | 193 | 303 | 212 | 51.2 | 144 | 118 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 442 | 51.2 | 193 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Adagene
ADAG
|
53.8 | $ 2.91 | 5.05 % | $ 164 M |  China |
 |
ANI Pharmaceuticals
ANIP
|
235 | $ 82.0 | 3.13 % | $ 1.58 B | USA |
 |
Aytu BioScience
AYTU
|
174 | $ 2.58 | -1.53 % | $ 16.2 M | USA |
 |
Biogen
BIIB
|
387 | $ 176.18 | 0.77 % | $ 25.7 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Catalyst Biosciences
CBIO
|
391 | $ 10.15 | -5.45 % | $ 668 M | USA |
 |
Cerus Corporation
CERS
|
59.2 | $ 2.32 | -1.69 % | $ 428 M | USA |
 |
Coherus BioSciences
CHRS
|
326 | $ 2.33 | 5.19 % | $ 219 M | USA |
 |
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Cellectis S.A.
CLLS
|
-839 | $ 3.99 | -1.72 % | $ 116 M |  France |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 69.12 | 5.4 % | $ 9.25 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
54.2 | $ 24.58 | 1.57 % | $ 2.91 B | USA |
 |
Cardiff Oncology
CRDF
|
284 | $ 1.62 | -0.31 % | $ 77.2 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
DBV Technologies S.A.
DBVT
|
71.3 | $ 22.96 | -3.41 % | $ 2.23 B | France |
 |
Amneal Pharmaceuticals
AMRX
|
123 | $ 14.11 | 1.15 % | $ 4.36 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |